|
Astellas Pharma US, Inc., is the U.S. affiliate of Astellas Pharma Inc., Japan’s second largest pharmaceutical company and ranked within the top 20 in the global market. Astellas Pharma US is located in Deerfield, Illinois, and is the company's North American headquarters.
Below are facts about Astellas Pharma US, including the company's key U.S. products, corporate information, and product highlights.
Astellas Pharma US, Inc.
| Company Name
| Astellas Pharma US, Inc.
(U.S. affiliate of Astellas Pharma Inc.) |
| North American Headquarters
| Three Parkway North
Deerfield, IL. 60015-2548
Phone: 1 (800) 695-4321
|
| U.S. Representative Director
| Mr. Seigo Kashii
President and Chief Executive Officer
Astellas Pharma US, Inc.
|
| U.S. Employees
| 1,900 (May 2009) |
| North American Product Sales
| $1.9 billion (May 2009)* |
| Key U.S. Products
|
|
| Key U.S. Pipeline Products |
- KynapidTM (vernakalant hydrochloride)— Investigational atrial selective antiarrhythmic drug for the treatment of atrial fibrillation (irregular rhythms in the heart’s upper chambers)
- Telavancin—Investigational antibiotic for complicated skin and skin structure infections (cSSSI) and hospital-acquired pneumonia (HAP)
|
| Major U.S. Corporate Highlights
|
- April 2005—Astellas establishes U.S. headquarters near Chicago with the merger of Yamanouchi & Fujisawa
- November 2005—Astellas and Theravance, Inc. announce collaboration on telavancin, an investigational antibiotic for serious infections
- March 2006—Astellas establishes Urogenix, Inc., expanding research capabilities in urology
- November 2007—Astellas acquires Agensys, Inc. a leading biotech in therapeutic antibody research and development in cancer
- March 2008—Astellas establishes Astellas Pharma Global Development, Inc. as new global development headquarters in U.S.
|
| Recent Major U.S. Product Highlights |
- January 2008—FDA approves additional indication for Mycamine®
- April 2008—FDA approves LexiscanTM, a pharmacologic stress agent developed in partnership with CV Therapeutics for use in radionuclide myocardial perfusion imaging (MPI)
- October 2008—FDA approves a new premixed formulation of Vaprisol®
- May 2009—FDA approves new indication for Prograf® for the prevention of organ rejection in kidney transplant recipients
|
* Includes sales from the U.S. and Canada
Adenocard® is a registered trademark of Astellas Pharma US, Inc.
Lexiscan® is a registered trademark of Astellas U.S. LLC.
Vaprisol® is a registered trademark of Astellas Pharma US, Inc.
INTRAVIA® is a registered trademark of Baxter International, Inc. (only should be used when referencing Vaprisol (conivaptan hydrochloride injection) Premixed in 5% Dextrose)
Protopic® is a registered trademark of Astellas Pharma Inc.
Amevive® is a registered trademark of Astellas U.S. LLC.
Prograf® is a registered trademark of Astellas Pharma Inc.
AmBisome® is a registered trademark of Gilead Sciences, Inc.
Mycamine® is a registered trademark of Astellas Pharma Inc.
Flomax® is a registered trademark of Boehringer Ingelheim. Flomax® was discovered by Yamanouchi and has been licensed to Boehringer Ingelheim for marketing since the U.S. launch in 1997. Astellas co-promotes Flomax® in the U.S. This partnership started in October 2004.
VESIcare® is a registered trademark of Astellas Pharmaceuticals Inc. VESIcare® is co-promoted with GlaxoSmithKline in the U.S.
KynapidTM (vernakalant hydrochloride) is in development in conjunction with Cardiome Pharma Corporation.
Telavancin is in development in conjunction with Theravance, Inc.
|
